Colchicine Tablets, USP 0.6 mg, Rx Only, a) 30 tablets per bottle, NDC 16714-0039-01, b) 100 tabl...

FDA Drug Recall #D-0467-2023 — Class III — February 24, 2023

Recall Summary

Recall Number D-0467-2023
Classification Class III — Low risk
Date Initiated February 24, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Zydus Pharmaceuticals (USA) Inc
Location Pennington, NJ
Product Type Drugs
Quantity 21,936/30 count bottles and 33,096/100 count bottles

Product Description

Colchicine Tablets, USP 0.6 mg, Rx Only, a) 30 tablets per bottle, NDC 16714-0039-01, b) 100 tablets per bottle, NDC 16714-0039-02, Manufactured for: NorthStar Rx LLC., Memphis, TN 38141, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, c) 100 tablets per bottle, NDC 70710-1351-01, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Reason for Recall

Failed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine.

Distribution Pattern

AZ, OH, MS.

Lot / Code Information

Lot #s: a) E203821, Exp. 05/2024; b) E203822, Exp. 05/2024, E206186, Exp. 10/2024; c) E203820, Exp. 05/2024.

Other Recalls from Zydus Pharmaceuticals (USA) Inc

Recall # Classification Product Date
D-0400-2026 Class II Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... Mar 9, 2026
D-0295-2026 Class II Icosapent Ethyl capsules, 1 gram, 120-count bot... Dec 30, 2025
D-0247-2026 Class III traZODONE Hydrochloride Tablets, USP, 100mg, 1,... Dec 19, 2025
D-0159-2026 Class II Bromocriptine Mesylate Capsules, USP, 5 mg, 30 ... Oct 23, 2025
D-0152-2026 Class II clomiPRAMINE Hydrochloride, Capsules, USP, 25 m... Oct 22, 2025

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.